NextCell Pharma: SEK15m directed issue and strategic update - Redeye

Redeye provides commentary on NextCell following the announcement of a SEK15m directed issue and a strategic update relating to its lead candidate ProTrans in type 1 diabetes. We adjust our valuation accordingly.

Länk till analysen i sin helhet: https://www.redeye.se/research/1145387/nextcell-pharma-sek15m-directed-issue-and-strategic-update?utm_source=finwire&utm_medium=RSS